Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

1.1K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.1K
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

1.6K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.6K
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

441
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
441
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

414
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
414
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

695
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
695
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

739
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
739

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of advanced imaging in the diagnosis and management of scimitar syndrome in pediatric patients.

International journal of cardiology. Congenital heart disease·2026
Same author

Safety and feasibility of deep sedation and general anaesthesia for cardiovascular MRI studies in paediatric patients from two tertiary European centres.

Cardiology in the young·2026
Same author

Evaluation of Third-Order Motion-Compensated Cardiac Diffusion Tensor Imaging Across Cardiac Phases Using an Ultra-High-Performance Clinical Scanner.

Magnetic resonance in medicine·2026
Same author

Optimized Reduced Field of View and Fat Suppression Methods for Interleaved Multislice In Vivo Cardiac Diffusion Tensor Imaging.

Magnetic resonance in medicine·2026
Same author

Prevalence and Clinical Importance of Right Ventricular Involvement in Mild Dilated Cardiomyopathy.

Journal of the American Heart Association·2026
Same author

Sotatercept improves right ventricular function but is associated with new or worsening pericardial effusions: a cardiovascular magnetic resonance study in intermediate-high risk pulmonary arterial hypertension.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance·2026
Same journal

Availability of mechanical circulatory support (MCS) and hospital survival in ST-segment elevation myocardial infarction related cardiogenic shock (STEMI-CS).

European heart journal. Acute cardiovascular care·2026
Same journal

Question: Imaging findings of an unexpected thoracic mass in a patient with prior valve repair.

European heart journal. Acute cardiovascular care·2026
Same journal

One-year and 5-year transition risks between major bleeding, reinfarction and death following Acute Myocardial Infarction in England and Wales: A population-based cohort study.

European heart journal. Acute cardiovascular care·2026
Same journal

Associations Between Admission C-Reactive Protein and In-Hospital Mortality Amongst Patients with Cardiogenic Shock.

European heart journal. Acute cardiovascular care·2026
Same journal

Safety and Efficacy of Ivabradine in the Treatment of Patients with Acute Myocardial Infarction: A Real-World Propensity Score Matching Study.

European heart journal. Acute cardiovascular care·2026
Same journal

Letter to the editor "Utilization patterns and determinants of guideline-recommended therapies for acute heart failure in Denmark".

European heart journal. Acute cardiovascular care·2026
See all related articles

Related Experiment Video

Updated: Mar 27, 2026

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

17.2K

Cardiac Myosin-binding Protein C in ST-elevation Myocardial Infarction.

Ramyah Rajakulasingam1,2, Bashir Alaour3, Sam McGrath3

  • 1National Heart and Lung Institute, Imperial College London, UK.

European Heart Journal. Acute Cardiovascular Care
|March 26, 2026
PubMed
Summary
This summary is machine-generated.

Cardiac myosin-binding protein C (cMyC) shows potential as an early biomarker for myocardial injury in ST-elevation myocardial infarction (STEMI). While it correlates with infarct size, cardiac troponins demonstrate superior performance in identifying microvascular obstruction.

Keywords:
ST-elevation myocardial infarctioncardiac myosin-binding protein Chigh-sensitivity cardiac troponin Imicrovascular obstructionmyocardial infarction sizemyocardial injury

More Related Videos

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.8K
A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.9K

Related Experiment Videos

Last Updated: Mar 27, 2026

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

17.2K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.8K
A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.9K

Area of Science:

  • Cardiology
  • Biomarker Discovery
  • Myocardial Infarction Research

Background:

  • Cardiac myosin-binding protein C (cMyC) is a novel biomarker for myocardial injury.
  • cMyC kinetics are faster than cardiac troponins, suggesting earlier diagnostic potential.
  • Its utility in reperfused ST-segment elevation myocardial infarction (STEMI) requires evaluation against established biomarkers.

Purpose of the Study:

  • To assess the correlation of cMyC with acute and final myocardial infarction (MI) size using late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR).
  • To determine if cMyC levels are associated with acute microvascular obstruction (MVO) detected by CMR.
  • To compare cMyC performance against high-sensitivity cardiac troponin I (hs-cTnI) and CMR findings.

Main Methods:

  • Blood samples were collected for cMyC and hs-cTnI measurements at 6-hour intervals for 24 hours post-reperfusion in STEMI patients.
  • Late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) was performed at approximately 3-5 days and 4 months post-reperfusion.
  • Correlation and discriminatory analyses were conducted to compare cMyC and hs-cTnI with MI size and MVO.

Main Results:

  • Acute cMyC levels significantly correlated with acute and final MI size, with the strongest correlation at 6 hours post-reperfusion (r=0.7).
  • cMyC at 6, 12, 18, and 24 hours showed discriminatory power for acute MVO, with the 6-hour level being most effective.
  • Hs-cTnI showed stronger correlations with MI size and superior discriminatory ability for MVO at later time points (12, 18, 24 hours).

Conclusions:

  • cMyC serves as a quantitative biomarker of myocardial injury in reperfused STEMI.
  • Further research with optimized high-sensitivity assays is needed to fully explore cMyC's potential as a novel post-MI biomarker.
  • Hs-cTnI remains a stronger biomarker for assessing MI size and MVO in the early hours post-reperfusion.